<DOC>
	<DOCNO>NCT00032643</DOCNO>
	<brief_summary>Congestive heart failure ( CHF ) affect 4-5 million Americans , prevalence predict increase next decade . Thyroid hormone unique action make novel potentially useful agent treatment CHF . Due possible adverse affect thyroid hormone , interest develop analog fewer undesirable side effect . 3,5- diiodothyropropionic acid ( DITPA ) show improve diastolic function animal model recently complete double-blind placebo control trial 19 human . The goal propose Phase II study show safety demonstrate medication efficacy DITPA need patient CHF . This study prerequisite large Phase III trial would determine whether mortality improve DITPA . To good define appropriate dos , prior Phase II study conduct initial pharmacokinetic study .</brief_summary>
	<brief_title>A Thyroid Hormone Analog Fight Heart Failure : Phase II Trial ( DITPA )</brief_title>
	<detailed_description>Intervention : After enrollment , patient receive clinical assessment , echocardiogram laboratory study . Then , patient receives treatment one two dose 3,5-diiodothyropropionic acid ( DITPA ) placebo six month . Primary hypothesis : DITPA improve cardiovascular function clinical status patient moderately severe heart failure similar placebo safety measure . Secondary hypothesis : Primary Outcomes : 1 . Composite endpoint compose cardiovascular mortality/morbidity , change NYHA class change global assessment , 2. safety . Study Abstract : Congestive heart failure ( CHF ) affect 4-5 million Americans , prevalence predict increase next decade . Thyroid hormone unique action make novel potentially useful agent treatment CHF . Due possible adverse effect thyroid hormone , interest develop analog fewer undesirable side effect . DITPA show improve diastolic function animal model recently complete double-blind placebo control trial 19 human . The goal propose Phase II study define dose DITPA need achieve hemodynamic improvement patient CHF . This study prerequisite large Phase III trial would determine whether mortality improve DITPA . To good define appropriate dos , prior Phase II study conduct initial pharmacokinetic study .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>INCLUSION To enrol , patient must : 1. veteran , 2. moderately severe CHF ( NYHA class II , III IV ) , 3. 18 old , 4. clinically important renal , hepatic hematological disorder clinically significant abnormal laboratory finding , 5. preexist thyroid disease , 6. anemia ( hematocrit le 30 % ) , 7. chronic pulmonary disease limit exercise tolerance require use chronic bronchodilator therapy steroid , 8. able walk level 6 minute , 9. hemodynamically significant pericardial disease , 10. angina pectoris severe enough require frequent administration sublingual nitroglycerin , 11. acute myocardial infarction within 6 month screen , 12. inoperable aortic stenosis , 13. symptomatic ventricular arrhythmia ventricular arrhythmia require pharmacological therapy , 14. implanted cardioverter defibrillator , 15. take amiodarone , 16. demonstrate noncompliance prior medical regime ; 17. investigational drug , 18. medical condition , investigator 's opinion , would make patient ineligible , 19. allergy iodine shellfish , 20. sinus rhythm , 21. childbearing potential , 22. ejection fraction great 40 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>